The unit includes 3,980 sq ft of high security storage space, as well as packaging and distribution areas for compounds covered by the US Drug Enforcement Administration’s (DEA) schedule I – V regulations.
Spokesman Jonathon Calderwood told Outsourcing-pharma.com that pharmaceutical industry demand and the evolution of the drug sector were the key drivers for Almac’s investment.
“Controlled drugs in terms of clinical supply are increasing in prominence as Pharma looks to shift beyond the blockbuster development models and move into targeted, niche therapies.”
He went on to explain that the firm has provided storage and packaging of controlled drugs for some time “but now [with the new unit] we have aimed to provide extensive capacity for these product types.
“Also,” Calderwood continued “global distribution and supply chain management of controlled substance clinical supplies is a growing service area, so we are also progressing the supply chain management aspect via our global distribution depot network.”
The Northern Ireland-headquartered firm has been moving into the Souderton facility in a phased transition programme that began last September with the installation of its analytical testing and clinical supplies units.
Since then Almac has opened a clinical technologies unit, which runs the firms trial monitoring and reporting technology business, and a pharmacy and distribution warehouse.
And, just last month, the contract research organisation (CRO) announced that the Souderton, Pennsylvania facility’s contract analytical laboratories had been made operational.